key: cord-0823897-ckqohr85 authors: N'Guessan, A.; Tsitouras, A.; Sanchez-Quete, F.; Goitom, E.; Reiling, S. J.; Galvez, J. H.; Nguyen, T. L.; Nguyen, H. T. L.; Visentin, F.; Hachad, M.; Krylova, K.; Matthews, S.; Kraemer, S. A.; Stretenowich, P.; Bourgey, M.; Djambazian, H.; Chen, S.-H.; Roy, A.-M.; Brookes, B.; Lee, S.; Simon, M.-M.; Maere, T.; Vanrolleghem, P.; Labelle, M.-A.; Moreira, S.; Levade, I.; Bourque, G.; Ragoussis, J.; Dorner, S.; Frigon, D.; Shapiro, B. J. title: Detection of prevalent SARS-CoV-2 variant lineages in wastewater and clinical sequences from cities in Quebec, Canada date: 2022-02-01 journal: nan DOI: 10.1101/2022.02.01.22270170 sha: e00e0e2489501482d6d65be7d896e494cb50f8cc doc_id: 823897 cord_uid: ckqohr85 Wastewater-based epidemiology has emerged as a promising tool to monitor pathogens in a population, particularly when clinical diagnostic capacities become overwhelmed. During the ongoing COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), several jurisdictions have tracked viral concentrations in wastewater to inform public health authorities. While some studies have also sequenced SARS-CoV-2 genomes from wastewater, there have been relatively few direct comparisons between viral genetic diversity in wastewater and matched clinical samples from the same region and time period. Here we report sequencing and inference of SARS-CoV-2 mutations and variant lineages (including variants of concern) in 936 wastewater samples and thousands of matched clinical sequences collected between March 2020 and July 2021 in the cities of Montreal, Quebec City, and Laval, representing almost half the population of the Canadian province of Quebec. We benchmarked our sequencing and variant-calling methods on known viral genome sequences to establish thresholds for inferring variants in wastewater with confidence. We found that variant frequency estimates in wastewater and clinical samples are correlated over time in each city, with similar dates of first detection. Across all variant lineages, wastewater detection is more concordant with targeted outbreak sequencing than with semi-random clinical swab sampling. Most variants were first observed in clinical and outbreak data due to higher sequencing rate. However, wastewater sequencing is highly efficient, detecting more variants for a given sampling effort. This shows the potential for wastewater sequencing to provide useful public health data, especially at places or times when sufficient clinical sampling is infrequent or infeasible. time in each city, with similar dates of first detection. Across all variant lineages, wastewater 48 detection is more concordant with targeted outbreak sequencing than with semi-random 49 clinical swab sampling. Most variants were first observed in clinical and outbreak data due to 50 higher sequencing rate. However, wastewater sequencing is highly efficient, detecting more 51 variants for a given sampling effort. This shows the potential for wastewater sequencing to 52 provide useful public health data, especially at places or times when sufficient clinical sampling 53 is infrequent or infeasible. 54 Quebec has been one of the Canadian provinces most affected by the COVID-19 pandemic, 56 with 5,698 cases and 135 deaths per 100,000 inhabitants as of December 2021 (Public Health 57 Agency of Canada 2021). After the first reported COVID-19 cases at the end of February 2020, 58 the government implemented public health measures to control the spread of the virus, 59 Wastewater also has the potential to capture mutations and variant lineages not observed in 92 human clinical samples, potentially including animal reservoirs (Smyth et al. 2021 ). However, 93 more studies are required to assess the sensitivity and spatio-temporal resolution of 94 wastewater sequencing in comparison to clinical sequencing. 95 Wastewater and clinical SARS-CoV-2 sampling and sequencing in Quebec 98 As a demonstration of WW-based VOCs and VOIs surveillance, we deep-sequenced SARS-99 CoV-2 genome-wide amplicons from 936 WW samples collected between March 2020 and 100 July 2021 in the cities of Montreal, Quebec, and Laval, representing almost half of Quebec's 101 population. The WW samples were collected from interceptors at the end of the WW network 102 (36.1%), residential areas (29.9%), WW treatment facilities (21.2%), prisons (7.69%), 103 industrial zones (4.90%) and long-term care and housing centers (0.21%). We compare the 104 WW data to semi-random clinical samples from the same cities, which we refer to as the 105 clinical dataset (N = 13,296 sequences), and non-random priority sequencing of outbreaks 106 and other samples of particular public health interest (e.g. suspected Alpha variant cases in 107 early 2021, travel-related cases, etc.), which we refer to as 'outbreak' samples (N = 5,661 108 sequences). 109 110 To study the genomic diversity of SARS-CoV-2 in WW samples, we first developed a 112 bioinformatic pipeline to confidently identify single nucleotide variants (SNVs) while accounting 113 for sequencing errors, then to infer VOIs, VOCs, and other variant lineages that contain 114 combinations of signature SNVs (Methods). WW samples can contain a mixture of variants 115 at different frequencies. True SNVs can be confused with errors that are introduced by sample 116 processing, e.g. from errors introduced by the reverse transcriptase or the polymerase that 117 are used for targeted SARS-CoV-2 amplification, or from read errors created by the 118 sequencing platform. In this study, we chose illumina sequencing to minimize the per-read 119 error rate (compared to Oxford Nanopore). To set appropriate thresholds for minimum SNV 120 frequencies and coverage, we sequenced 14 SARS-CoV-2 positive control genomes from 121 AccuGenomics, containing a set of known SNVs at 100% within-sample frequency, which we 122 sequenced using the same Illumina amplicon strategy used for the WW samples. We 123 assessed a range of filters for depth of coverage and minor allele frequency (MAF) required 124 to call a SNV (Figure 1 ). Our SNV calling pipeline yields systematically low false positive rates 125 (median < 7% even at 1% MAF and effectively zero at 25% MAF) across a range of filters and 126 expected frequency of the true positive SNVs (Figure 1) . To be conservative for subsequent 127 analyses we selected a minimum site coverage of 50X and a MAF of 25%. These filters 128 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 maximized the F1 score, which combines information about the precision (i.e. the proportion 129 of SNV calls that are true positives) and the sensitivity (i.e. the proportion of true variants that 130 are identified). The F1 scores are poor when the expected frequency of the true positive SNVs 131 is 100% (Figure S1A ) but improves when we allow the expected nucleotide to have a 132 frequency of at least 75% to allow for sequencing errors ( Figure S1B) . Note that very similar 133 F1 scores were obtained at 10% MAF and that our variant calling pipeline can detect low-134 frequency mutations with high accuracy (Figures 1 and S2 ), but we proceeded with 25% to 135 be conservative. In addition to the AccuGenomics controls, we also sequenced mixtures of 136 two different SARS-CoV-2 viral cultures at known ratios, which we call "spike-in" samples. We 137 found that our SNV-calling pipeline identified the expected SNVs close to their expected 138 frequencies. Low variant frequencies (expected frequency < 5%) were inferred particularly 139 accurately, with more variation in the 25-50% range ( Figure S2) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10. 1101 /2022 Sampling and sequencing SARS-CoV-2 from wastewater 150 Having established a reliable method for SNV calling, we applied it to a set of 936 WW samples 151 collected between March 2020 and July 2021 in Montreal, Quebec City, and Laval (Table S1) . 152 Because SNV calling requires sufficient depth of coverage, we measured how coverage depth 153 and breadth varied across the SARS-CoV-2 genome in our samples (Figure 2) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10. 1101 /2022 The mean depth and breadth of coverage varied somewhat across genes, and was roughly 166 bimodal, with samples tending to fall either close to 0-1X coverage or >1000X on average, 167 with fewer samples in between (Figure 2 ). As expected, coverage correlated negatively with 168 PCR Cycle threshold (linear regression adjusted R 2 = 19.2%; Permutational ANOVA p < 2e-169 4, n = 5000 permutations), as previously observed (Lythgoe et al. 2021; Baaijens et al. 2021). 170 Due to this variation in coverage, not all nucleotide sites in the genome in all samples have 171 sufficient depth to make SNV calls. However, given the substantial number of samples with 172 >1000X coverage, we expect to obtain a reasonable number of high-confidence SNVs in our 173 dataset. Using the >=50X coverage and 25% MAF filters described above, we called an 174 average of 6.87 SNVs per sample (s.d. = 10.1) ( Figure S3) . 175 176 Detecting SARS-CoV-2 lineages in wastewater using signature and marker mutations 177 With these SNVs in hand, we sought to infer the presence of known variant lineages in WW 178 samples. We defined "signature mutations" as SNVs with a minimum prevalence of 90% 179 among the consensus sequences of a certain lineage (e.g. a particular VOC represented in a 180 database). To find these signature mutations, we first calculated the prevalence of 181 substitutions in thousands of publicly available consensus sequences collected during 2020 182 and added data from CoV-Spectrum (Chen et al. 2021) to include under-represented lineages 183 or lineages that emerged after 2020 (Methods). These variant lineages were named using 184 the PANGO lineage designation scheme (Rambaut et al. 2020) . We further defined "marker 185 mutations" as signature mutations that are unique to a single variant lineage to the exclusion 186 of others. 187 Using these criteria, we identified an average of 4.42 signature mutations per sample 188 (s.d. = 6.94) and 2.01 marker mutations per sample (s.d. = 3.22) ( Figure S3 ). To call a variant 189 lineage as present in a WW sample, we required at least 3 signature mutations including at 190 least one marker mutation (Methods), yielding an average of 0.79 variant lineages identified 191 per sample (s.d. = 1.14; min.=0; max. = 6). This approach allowed us to track the spread of 192 variants with a confidence score, i.e. the number of signature mutations supporting the 193 presence of a lineage, which includes at least one of its marker mutations ( Figure S4 and 194 We also estimated the within-sample frequency of variant lineages using constrained 197 linear models (Methods). These models infer the linear combination of known variant lineages 198 (from the database of reference genomes) that best explain the frequencies of observed SNVs 199 in the sample ( Figure S6 ). We applied this approach to the 299 WW samples that have at 200 least one lineage with at least 3 signature mutations, including at least one marker mutation. 201 Among these samples, the regression model was significant for 250 samples (83.6%) and not 202 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101/2022.02.01.22270170 doi: medRxiv preprint significant for the remaining 49 samples (16.4%). These variant frequency estimates ( Figure 203 S5) were generally concordant with the simpler approach relying on signature and marker 204 mutations ( Figure S4) . Both approaches showed a predominance of the Alpha variant in all 205 cities, with substantial numbers of B.1.160 in 2020 and early 2021, and A.2.5.X lineages 206 previously described in Quebec clinical samples (Murall et al., 2021) . 207 The absence of variant lineage detections can simply be due to lack of sampling, lack 208 of sequencing depth, or a true absence. Sampling frequency is indeed variable over time and 209 cities ( Figure S7 ) and the absence of detections is mostly explained by the absence of WW 210 samples (81.4% of time points with missing lineages; grey shading in Figures S4 and S5) and 211 modestly by lack of sufficient sequencing depth (18.6%; transparent red shading in Figures 212 S4 and S5 ). This suggests that increased sampling frequency, coupled with modest 213 optimization of RNA extraction and sequencing protocols, could increase both the true positive 214 and true negative rates. 215 216 To assess how SARS-CoV-2 variant lineage detection in wastewater compared with 218 sequencing of clinical samples in the same cities and time period, we considered the top three 219 most prevalent lineages detected in our WW samples: Alpha (B.1.1.7), B.1.160, and A.2.5.X). 220 For these analyses, we supplemented the 936 WW sequences with 13,296 clinical samples 221 from a semi-random population sample of nasal swabs (of which 9,262 passed sequencing 222 quality filters and were deposited in GISAID; Table S3 ) and 5,661 non-random 'outbreak' 223 samples sequenced with high priority by the Quebec Public Health lab (of which 1,848 passed 224 filters and were deposited in GISAID; Table S4 ; Methods). In each sample type, we defined a 225 variant lineage's frequency relative to other lineages in a 2-week time window. The frequency 226 estimates from WW and both types of clinical samples are significantly correlated (linear 227 regression adjusted R 2 = 0.63 with semi-random clinical data, and 0.34 with outbreak data; 228 Permutational ANOVA both p < 2e-4, pooled over the three most prevalent variants; n = 5000 229 permutations). Note that this method ignores missing data, so sampling gaps do not contribute 230 to the regression. In general, variants are detected first in clinical or outbreak data, and shortly 231 thereafter in wastewater (Figure 3) . The Alpha VOC (B.1.1.7) in particular tended to be 232 detected first in outbreak samples, likely because suspected Alpha cases were prioritized for 233 sequencing by the Quebec Public Health lab at the time. Notably, Alpha was detected in WW 234 concurrently or shortly after outbreak samples, despite being detected much later (or not at 235 all) in semi-random clinical sequences (Figure 3) . 236 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. September 2020 because sampling frequency was sparse before that ( Figure S7 ). 245 246 Next, we sought to generalize these results beyond the most prevalent variants and to 247 consider different possible time-lags between clinical and WW samples. For example, clinically 248 undetected asymptomatic or pre-symptomatic cases could be detected earlier with WW 249 sampling. Conversely, outbreak and clinical samplings might detect some lineages earlier than 250 WW when the testing rate is high and appropriately targeted. We considered time lags 251 between 0 and 8 days between collection of WW and clinical or outbreak samples, and 252 calculated concordance, defined simply as the detection of a variant in both sample types. We 253 found that concordance was maximized between WW and both clinical or outbreak samples 254 at a maximum time lag of around 7 days, regardless of the number of signature SNVs required 255 to define variants (Figures S8 and S9 ). The 7-day time interval is similar to the average pre-256 symptomatic phase duration, i.e. 6.4 days (Backer, Klinkenberg, and Wallinga 2020) . To 257 assess the significance of these concordance scores, we permuted (1000 times) the variant 258 detections across cities and time (days) and compared the concordance score after 259 permutations to the original concordance score to obtain a p-value. Using a 7-day maximum 260 time lag and defining variants with at least three signature SNVs, we estimated that 41.7% of 261 WW calls are concordant with semi-random clinical sampling data (permutation test p-value = 262 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. is consistent with another study from the United States (Baaijens et al. 2021 ) and is explained 282 by a higher monthly sequencing rate ( Figure S11B) . However, at an equal sequencing rate, 283 WW is able to detect more variant lineages than clinical or outbreak sampling (Figure 4) . This 284 suggests that, for a given sequencing effort, WW surveillance could detect a higher diversity 285 of variants. Even in our current limited sample of 936 WW sequences, we are able to infer the 286 presence of certain variants that are not apparent in clinical sequences ( Figure S10) . 287 288 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Using a relatively conservative SNV calling pipeline and lineage detection method, we tracked 297 the spread of SARS-CoV-2 lineages in wastewater between March 2020 and July 2021 across 298 three cities in the province of Quebec. Although WW sequencing could be used to detect novel 299 mutations or variant lineages not found in clinical samples (Smyth et al. 2021 ), here we 300 focused on identifying known variants. Consistent with a similar study in the US, we found that 301 sequencing coverage in WW was dependent on viral load, as measured by the qPCR cycle 302 threshold (Ct) value (Baaijens et al. 2021) . This suggests that WW sample concentration or 303 optimization of RNA extraction could yield more sequence data and improve variant inference. 304 We also found that the most prevalent variants were detected concordantly in WW and clinical 305 samples over a 7-day time frame, but that variants were generally detected first in clinical 306 samples, suggesting that clinical diagnostics efforts were effective at the time of sampling. We is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 To perform the genomic surveillance of SARS-CoV-2, we collected WW samples at the 380 institutional, district, and municipal scale from Montreal, Quebec City, and Laval. The samples 381 were collected by composite sampling, grab sampling, and passive sampling. The composite 382 samples were collected with autosamplers, which collected wastewater every 10 minutes, over 383 a 24, 48, or 72 hour time period. The passive samples were collected through 2 absorbent 384 materials, Q-tips and negatively charged membranes, Mixed Cellulose Ester (MCE) filters, 385 which were housed in torpedoes (Schang et al. 2021 (Li 2011; Koboldt et al. 2012) . To select coverage and SNV frequency 412 filters for SNV calling, we analyzed 14 positive controls from AccuGenomics for which we 413 know the list of expected mutations (https://accugenomics.com/accukit-sars-cov-2/). These 414 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101/2022.02.01.22270170 doi: medRxiv preprint controls allow us to measure a limit of detection and to evaluate the background error due to 415 library preparation, sequencing, or other sources of noise. Using these controls, we can then 416 determine the variant calling filters that allows to minimize the background error, i.e. the false 417 positive and false negative rates, and maximizes the accuracy of SNV calling, i.e. F1 score. 418 We calculated this score using the precision, i.e. the proportion of SNV calls (positives) that 419 are true positives, and the recall/sensitivity, i.e. the proportion of expected variants that have 420 been called (Powers 2020) . The SNV calling and post-variant-calling pipeline is available at 421 https://github.com/arnaud00013/Wastewater_surveillance_pipeline. 422 In addition to the AccuGenomics controls, we also sequenced mixtures of two different 423 SARS-CoV-2 viral cultures at known ratios, which we called "spike-in" samples. In these 424 samples, a viral culture extract was spiked into a SARS-CoV-2 positive control sample at a 425 concentration of 1%, 2%, 5%, 10%, 20% or 50%. Both samples were obtained from the first 426 wave of the pandemic and differed by 11 mutations . We performed variant calling on the 427 sequenced spiked-in samples based on the same method as the WW samples, except for the 428 VAF filter, which we removed to be able to detect expected low-frequency mutations. sequences from a certain lineage, are required to call a lineage present in a WW sample. We 450 selected this filter arbitrarily as a compromise between confidence of detection and 451 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 1, 2022. ; https://doi.org/10.1101/2022.02.01.22270170 doi: medRxiv preprint sensitivity/stringency. We also made sure to evaluate the effect of selecting different filters on 452 the concordance between WW and clinical sampling. 453 For the calculation of within-sample frequency of SARS-CoV-2 lineages, we used a 454 linear model to fit the lineages' signature mutations data to the within-sample mutation 455 frequency data. The rationale of the approach is that the frequency of lineage signature 456 mutations within a sample is a linear combination of the frequency of the lineages and the 457 prevalence of the mutations in the consensus sequences of these lineages. To make sure that 458 linear regression converged to a good solution, we needed to apply certain constraints (Figure 459 Variant Abundance Estimation for 468 SARS-CoV-2 in Wastewater Using RNA-Seq Quantification Incubation Period of 472 2019 Novel Coronavirus (2019-nCoV) Infections among Travellers from Wuhan Making Waves: 477 Plausible Lead Time for Wastewater Based Epidemiology as an Early Warning System 478 for COVID-19 Increased Transmissibility and Global Spread of 482 SARS-CoV-2 Variants of Concern as at CoV-Spectrum: Analysis of Globally Shared SARS-487 CoV-2 Data to Identify and Characterize New Variants Fastp: An Ultra-Fast All-in-491 Genome Sequencing of Sewage 495 Detects Regionally Prevalent SARS-CoV-2 Variants Transmissibility and Impact of SARS-CoV-2 Lineage B.1.1.7 in England Définitions Pour La Vigie 503 Sanitaire Des Variants Du SRAS-CoV-2 et Classification Des Lignées Détectées Au 504 Shedding of 509 SARS-CoV-2 in Feces and Urine and Its Potential Role in Person Transmission and the Environment-Based Spread of COVID-19 VarScan 2: Somatic Mutation and Copy Number Alteration Discovery in Cancer by 516 A Statistical Framework for SNP Calling, Mutation Discovery Association Mapping and Population Genetical Parameter Estimation from Sequencing 520 Data SARS-CoV-2 within-527 Host Diversity and Transmission SARS-CoV-2 B.1.617.2 Delta 532 Variant Replication and Immune Evasion A Small Number of Early 537 Introductions Seeded Widespread Transmission of SARS-CoV-2 in Québec, Canada Recent 542 Evolution and International Transmission of SARS-CoV-2 Clade 19B The Origins and Potential Future of SARS-CoV-2 Variants 548 of Concern in the Evolving COVID-19 Pandemic Evaluation: From Precision, Recall and F-Measure to 552 Markedness and Correlation COVID-19 Daily Epidemiology Update A Dynamic 561 Nomenclature Proposal for SARS-CoV-2 Lineages to Assist Genomic Epidemiology R: A Language and Environment for Statistical 565 Computing Passive Sampling of SARS-CoV-2 for Wastewater 569 Surveillance Tracking Cryptic SARS-CoV-2 Lineages 573 Detected in NYC Wastewater 1.1.7 in England Metrics to Relate COVID-19 Wastewater Data to Clinical 581 Testing Dynamics